Form 4: ANI Pharmaceuticals CEO Nikhil Lalwani Reports Stock Transaction
SEC Form 4 Filing
Nikhil Lalwani, President & CEO of ANI Pharmaceuticals, reports the disposition of 3,646 shares of common stock to cover tax obligations related to vesting restricted stock.
Summary
- On September 8, 2024, Nikhil Lalwani, the President & CEO of ANI Pharmaceuticals, disposed of 3,646 shares of common stock.
- The transaction was executed at a price of $60.51 per share.
- These shares were withheld for tax purposes related to the vesting of 7,127 shares of restricted stock.
- Following the transaction, Lalwani directly owns 373,859 shares of ANI Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock transactions, and does not contain any information that would significantly impact investor sentiment positively or negatively.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a standard tax-related transaction following the vesting of restricted stock.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine tax-related disposal of shares.
Key Dates
| Date | Description |
|---|---|
| 09/08/2024 | Date of stock transaction (disposal of shares). |
| 09/10/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.